- Omalizumab, sold
under the
brand name
Xolair among others, is an
injectable medication to
treat severe persistent allergic forms of asthma,
nasal polyps...
-
acquired Tanox in its
first acquisition deal.
Tanox had
started developing Xolair and
development was
completed in
collaboration with
Novartis and Genentech;...
- In the
first approach, the anti-IgE
antibody drug
omalizumab (trade name
Xolair)
recognises IgE not
bound to its
receptors and is used to
neutralise or...
- (baloxavir marboxil), for
influenza A and B (both
treatment and prevention).
Xolair (omalizumab), for asthma,
chronic idiopathic urticaria (CIU), and nasal...
- and
ophthalmology divisions,
managed the
sales of Rituxan, Raptiva, and
Xolair, and
directed Roche's late-stage
portfolio committee for
nearly four years...
- Genentech, a
Roche subsidiary. One
agreement is for Lucentis; the
other is for
Xolair.: 239 In 2014,
Novartis established a
center in Hyderabad, India, in order...
- in the
event of a
serious reaction.
Studies have
found that
omalizumab (
Xolair) may be an
effective and safe
treatment for cold
urticaria in
patients who...
- allergy-related
basis of asthma,
Xolair. In June 2003, the U.S. Food and Drug
Administration (FDA)
approved Xolair, the
first biotech product cleared...
- antibody-based
therapeutics lead to the
development of
omalizumab (also
known as
Xolair), a
medication that has been
approved for the
treatment of
severe allergic...
-
vaccine 209,367 6.41%
Pfizer Pneumococcal disease Feb-2000 Jan-2007 82
Xolair Omalizumab 207,891 1.91% Genentech,
Novartis Asthma 2003 Mon-20XX 83 Lipitor...
